The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1359-1364

  Ferraz, Marcela L ^a   Gazzinelli, Ricardo T ^a,b   Alves, Rosana O ^a   Urbina, Julio A ^c   Romanha, Alvaro J ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Centro de Ingeniería de Materiales y Nanotecnología Instituto Venezolano de Investigaciones Científicas   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 12; POSACONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NITROIMIDAZOLES; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 34247144012     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01170-06     Document Type: Article

References (41)

1. Abrahamsohn, I. A., and R. Coffman. 1995. Cytokine and nitric oxide regulation of the immunosuppresion in Trypanosoma cruzi infection. J. Immunol. 155:3955-3963.
2. Aliberti, J. C. S., M. A. G. Cardoso, G. A. Martins, R. T. Gazzinelli, L. Q. Vieira, and J. S. Silva. 1996. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect. Immun. 64:1961-1967.
3. Bahia-Oliveira, L. M. G., J. A. S. Gomes, J. R. Cançado, T. C. Ferrari, E. M. Lemos, Z. M. P. Luz, M. C. Moreira, G. Gazzinelli, and R. Corrêa-Oliveira. 2000. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis. 182:634-638.
4. Berger, B. J., and A. H. Fairlamb. 1992. Interactions between immunity and chemotherapy in the treatment of trypanosomiases and leishmaniases. Parasitology 105:871-S78.
5. Brener, Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 4:389-396.
6. Brener, Z., and R. T. Gazzinelli. 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol. 114:103-110.
7. Camargo, E. P. 1964. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosome in liquid media. Rev. Inst. Med. Trop. Sao Paulo 6:93-100.
8. Cançado, J. R. 2002. Long term evaluation of etiological treatment of Chagas disease with Benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44:29-37.
9. Corrales, M., R. Cardozo, M. A. Segura, J. A. Urbina, and M. A. Basombrio. 2005. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 49:1556-1560.
10. D'Avila, S. C., A. M. D'Ávila, C. Pagliari, V. M. Gonçalves, and M. I. Duarte. 2005. Erythema nodoso in reactivation of Chagas' disease after cardiac transplantation. Rev. Soc. Bras. Med. Trop. 38:61-63.
11. Doenhoff, M. J., A. A. A. Sabah, C. Fletcher, G. Webbe, and J. Bain. 1987. Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans. R. Trop. Med. Hyg. 81:947-951.
12. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
13. Galhardo, M. C. G., I. A. Martins, A. H. Moreno, S. S. Xavier, J. M. C. Coelho, A. C. V. Vasconcelos, and R. S. Ribeiro. 1999. Reativação da infecção por Trypanosoma cruzi em paciente com síndrome da imunodeficiência adquirida. Rev. Soc. Bras. Med. Trop. 32:291-294.
14. Gazzinelli, R. T., I. P. Oswald, S. Hieny, S. L. James, and A. Sher. 1992. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur. J. Immunol. 22:2501-2506.
15. Guedes, P. M., J. A. Urbina, M. de Lana, L. C. Afonso, V. M. Velosos, W. L. Tafuri, G. L. Machado-Coelho, E. Chiari, and M. T. Bahia. 2004. Activity of new triazole derivate albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog host. Antimicrob. Agents Chemother. 48:4285-4292.
16. Madalosso, G., A. C. Pellini, M. J. Vasconcelos, A. F. Ribeiro, L. Weissmann, G. S. Oliveira Filho, A. C. Penalva de Oliveira, and J. E. Vidal. 2004. Chagasic meningoencephalitis: case reported of a recently included AIDS-defining illness in Brazil. Rev. Inst. Med. Trop. Sao Paulo 46:199-202.
17. Michailowsky, V., S. M. F. Murta, L. Carvalho-Oliveira, M. E. S. Pereira, L. R. P. Ferreira, Z. Brener, A. J. Romanha, and R. T. Gazzinelli. 1998. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:2549-2556.
18. Michailowsky, V., N. M. Silva, C. D. Rocha, L. Q. Vieira, J. Lannes-Vieira, and R. T. Gazzinelli. 2001. Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central system during Trypanosoma cruzi infection. Am. J. Pathol. 159:1723-1733.
19. Molina, J., Z. Brener, A. J. Romanha, and J. A. Urbina. 2000. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J. Antimicrob. Chemother. 46:137-140.
20. Molina, J., O. Martins-Filho, Z. Brener, A. J. Romanha, D. Loebenberg, and J. A. Urbina. 2000. Activities of the triazole derivate SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44:150-155.
21. National Research Council. 2003. Manual on the care and use of laboratory animals. National Academy Press, Washington, DC.
22. Rassi, A., V. Amato Neto, A. F. Siqueira, F. F. Filho, V. S. Amato, G. G. Rassi, and A. Rassi, Jr. 2002. Tratamento da fase crônica da doença de Chagas com nifurtimox associado a corticóide. Rev. Soc. Bras. Med. Trop. 35:547-550.
23. Rassi, A., V. Amato Neto, A. F. Siqueira, F. F. Filho, V. S. Amato, and A. Rassi Jr. 1999. Efeito protetor do benznidazol contra a reativacao parasitária em pacientes cronicamente infectados pelo Trypanosoma cruzi e tratados com corticóides em virtude de afecções secundárias. Rev. Soc. Bras. Med. Trop. 32:475-482.
24. Rhalem, A., H. Sahibi, S. Lasri, and C. L. Jaffe. 1999. Analysis of immune responses in dogs with canine visceral leishmaniosis before, and after, drug treatment. Vet. Immunol. Immunopathol. 71:69-76.
25. Romanha, A. J., R. O. Alves, S. M. F. Murta, J. S. Silva, C. Ropert, and R. T. Gazzinelli. 2002. Experimental chemotherapy against Trypanosoma cruzi infection: role of endogenous interferon-γ in mediating parasitologic cure. J. Infect. Dis. 186:823-828.
26. Rottenberg, M. E., A. Riarte, L. Sporrong, J. Altcheh, P. Petray, A. M. Ruiz, H. Wigzell, and A. Orn. 1995. Outcome of infection with differents strains of Trypanosoma cruzi in mice lacking CD4 and/or CD8. Immunol. Lett. 45:53-60.
27. + T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188-10192.
28. Silva, A. P. G., J. F. Jacysyn, and I. A. Abrahamsohn. 2003. Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response. Immunity 108:230-237.
29. Silva, J. S., J. C. S. Aliberti, G. A. Martins, M. A. Souza, J. T. Souto, and M. A. Pádua. 1998. The role of IL-12 in experimental Trypanosoma cruzi infection. Braz. J. Med. Biol. Res. 31:111-115.
30. Silva, L. H. P., and V. Nussenzweigh. 1953. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin. Biol. 20:191-208.
31. Taliaferro, W. H. 1948. The role of the spleen and lymphoid macrophage system in the quinine treatment of Gallinaceum malaria. I. Acquired immunity and phagocytosis. J. Infect. Dis. 83:164-180.
32. Targett, G. A. 1985. Chemotherapy and the immune response in parasitic infections. Parasitology 90:661-673.
33. Tarleton, R. L., B. H. Koller, A. Latour, and M. Postan. 1992. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356:338-340.
34. Toledo, M. J. O., G. B. N. Machado, M. E. S. Pereira, and Z. Brener. 1991. Results of treatment in mice immunossupressed inoculated with different Trypanosoma cruzi strains. Mem. Inst. Oswaldo Cruz 836:237.
35. Torrico, F., H. Heremans, M. T. Rivera, E. van Marck, A. Billiau, and Y. Carlier. 1991. Endogenous IFN-γ is required for resistance to acute Trypanosoma cruzi infection in mice. J. Immunol. 146:3626-3632.
36. Urbina, J. A., G. Payares, C. Sanoja, J. Molina, M. M. Piras, R. Piras, N. Perez, P. Wincker, and D. Loebenberg. 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1771-1777.
37. Urbina, J. A., R. Lira, G. Visbal, and J. Bartroli. 2000. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44:2498-2502.
38. Urbina, J. A., and R. Docampo. 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19:495-500.
39. Urbina, J. A., R. Lira, Z. Brener, and A. J. Romanha. 2003. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21:39-48.
40. Urbina, J. A., G. Payares, C. Sanoja, R. Lira, and A. J. Romanha. 2003. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 21:27-38.
41. World Health Organization. 2002. Chagas disease. Tropical disease research, p. 112-123. In Eighteenth programme report of UDNPD/World Bank/WHO Special Programme for Research and Training in Tropical Disease Research: progress 1995-1996. World Health Organization, Geneva, Switzerland.